Trials / Terminated
TerminatedNCT03310593
Cannabidiol as an Adjunctive Treatment for Bipolar Depression
A Double-blind, Randomized, Placebo-controlled Clinical Trial of Adjunctive Cannabidiol for Bipolar Depression
- Status
- Terminated
- Phase
- Phase 2 / Phase 3
- Study type
- Interventional
- Enrollment
- 36 (actual)
- Sponsor
- Hospital de Clinicas de Porto Alegre · Academic / Other
- Sex
- All
- Age
- 18 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
Depressive symptoms are associated with significant psychosocial impairment. However, current treatments of bipolar depression are only partially effective. Cannabidiol is a natural component of cannabis without psychotomimetic or addictive properties. Cannabidiol has been shown to produce therapeutic effects including anticonvulsive, anxiolytic, antipsychotic and neuroprotective effects. The investigators hypothesize that treatment with cannabidiol will result in improvement of depressive and anxiety symptoms, as well as, improvement in functioning and inflammatory biomarkers. During the clinical trial, subjects will receive study medication (cannabidiol 150-300mg/day) or placebo for a period of 12 weeks.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Cannabidiol | Cannabidiol as active intervention. |
| DRUG | Placebo | Placebo intervention. |
Timeline
- Start date
- 2017-11-01
- Primary completion
- 2020-02-24
- Completion
- 2020-03-24
- First posted
- 2017-10-16
- Last updated
- 2021-07-02
Locations
1 site across 1 country: Brazil
Source: ClinicalTrials.gov record NCT03310593. Inclusion in this directory is not an endorsement.